Salarius Pharmaceuticals, Inc.
$0.8883
Stock Quotes & Analysis
SLRX1.17%
$0.8883
Latest AAPL News (Need to figure out how to make this dynamic)
test
Graphene is an excellent conductor of electricity and heat, surpassing traditional materials like silicon, and…
The political winds are shifting, and Wall Street is taking notice. As Donald Trump’s approval…
In the shadows of Silicon Valley’s AI frenzy, a sleeping giant is awakening. While tech…
Salarius Pharmaceuticals, Inc.Status: Active
Sector: Healthcare
Industry: Biotechnology
Symbol: SLRX
Exchange: NCM
Employees: 2
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
 | 2450 Holcombe Boulevard, Houston, TX, United States |
 | 832 834 9144 |
 | https://www.salariuspharma.com |